Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AGEN1423 · 1 trial · 3 indications
The objective response rate (ORR) is defined as the proportion of participants achieving complete response (CR) or partial response (PR) based on RECISTv1.1 criteria, using the modified intent-to-treat (mITT) analysis set
| Arm | Type | Description |
|---|---|---|
| COHORT 1: AGEN1423 Plus Botensilimab | EXPERIMENTAL | Treatment is AGEN1423 plus Botensilimab for 4 cycles (8 weeks) followed by Botensilimab alone for up to 2 years. AGEN1423 will be administered in a total of 4 doses. Botensilimab will be administered every 2 weeks. |
| COHORT 2: AGEN1423 Plus Botensilimab and Chemotherapy | EXPERIMENTAL | Treatment is AGEN1423 plus Botensilimab in combination with gemcitabine and nab-paclitaxel for 2 cycles (8 weeks) followed by Botensilimab in combination with gemcitabine and nab-paclitaxel for up to 2 years. AGEN1423 will be administered in a total of 4 doses. Botensilimab will be administered once every 2 weeks. |
| Name | Type | Description |
|---|---|---|
| AGEN1423 | DRUG | via IV, dosage per protocol, once every 2 weeks for up to 8 weeks |
| Botensilimab | DRUG | via IV, dosage per protocol, once evert 2 weeks, up to 2 years |
| Gemcitabine | DRUG | per standard care |
| Nab-paclitaxel | DRUG | per standard care |
Inclusion Criteria: * 18 year and older * Ability to understand and willingness to sign a written informed consent prior to entering the study. * Histologically or cytologically confirmed (either previously or newly biopsied) metastatic or locally advanced unresectable pancreatic adenocarcinoma, in...
AGEN1423 is an investigational small molecule being studied for the treatment of Advanced Pancreatic Ductal Adenocarcinoma (PDAC). It is currently in Phase 2 clinical development, evaluated in combination with botensilimab, with or without chemotherapy, in patients with this condition.
AGEN1423 targets CTLA-4, a protein involved in regulating immune responses. By targeting CTLA-4, AGEN1423 is designed to modulate the immune system's activity against cancer cells. This mechanism is being investigated in the context of advanced pancreatic ductal adenocarcinoma.
AGEN1423 is being developed by Agenus Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AGEN. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with advanced pancreatic ductal adenocarcinoma.
AGEN1423 is in Phase 2 clinical development. It is an investigational drug, not yet approved by regulatory authorities. The ongoing Phase 2 trial is actively enrolling participants to assess the drug's effects in advanced pancreatic ductal adenocarcinoma.
AGEN1423 is being studied in a Phase 2 clinical trial with the identifier NCT05632328. This trial, titled 'AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC', is active but not recruiting, with an enrollment of 24 participants in the United States.
No, AGEN1423 is not the same as botensilimab. AGEN1423 is a small molecule targeting CTLA-4, while botensilimab is a separate investigational agent. In the clinical trial NCT05632328, AGEN1423 is being studied in combination with botensilimab, with or without chemotherapy, for advanced pancreatic ductal adenocarcinoma.